(Q39127364)

English

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

scientific article published on September 2003

Statements

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English)
David R Colnot
Jan C Roos
Abraham J Wilhelm
J Alain Kummer
Gertraud Hanft
Karl-Heinz Heider
Gerd Stehle
Gordon B Snow
Guus A M S van Dongen
1 September 2003
576-582

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit